扬州优邦生物药品有限公司

What 扬州优邦生物药品有限公司 does

Yangzhou Uni-Bio Biological Pharmaceutical Co., Ltd. (扬州优邦生物药品有限公司), established in January 2004 and wholly acquired by Jinyu Bio Technology Co., Ltd. (Shanghai Stock Exchange: 600201) in 2007, is a Chinese veterinary biologics manufacturer focused on the research, development, production, and sale of vaccines for livestock, poultry, waterfowl, and ruminants. The company operates from a 66,484.4 sqm facility in the Yangzhou Weiyang Economic Development Zone (Jiangsu Province) with registered capital of RMB 100 million. It serves commercial pig, poultry, waterfowl, and cattle farms across China, addressing major infectious diseases including porcine reproductive and respiratory syndrome (PRRS/blue-ear disease), pseudorabies, swine influenza, porcine circovirus type 2, Newcastle disease, avian influenza H9, infectious bronchitis, gosling plague, and duck Tembusu virus disease.

The company's technical foundation rests on five proprietary R&D platforms: baculovirus expression, live viral vector vaccine development, large-scale animal cell suspension culture, reverse genetics, and multi-stage purification and concentration. These platforms support a portfolio of 22 production-permitted products (8 pig vaccines, 13 poultry vaccines, 1 cattle vaccine) manufactured across 8 GMP-certified production lines in 2 workshops. Differentiated process capabilities include endotoxin control standards ten times stricter than national requirements (≤5EU/dose versus 50EU), 146S antigen quantification via UV sucrose density gradient centrifugation (CNAS certified 2019, reducing animal testing by an estimated 25,000 heads per year nationally), and antigen protection processes that maintain near-zero degradation across the vaccine lifecycle. The R&D function is staffed by 38+ professionals, including 5 PhDs and 2 industrial professors, and is supported by long-standing research partnerships with Nanjing Agricultural University and Yangzhou University.

The company generates revenue through direct sales of veterinary vaccines to enterprise livestock and poultry farming operations via a national sales force organized by regional managers covering all major Chinese provinces (including dedicated pig vaccine and poultry vaccine sales hotlines). The go-to-market is sales-led B2B, supplemented by content marketing through the company website, technical articles, and trade show participation such as the China International Livestock Expo (CAHE). Pricing is not publicly disclosed. The company is regulated under veterinary GMP, ISO9001:2015, CNAS laboratory, and Veterinary GCP certifications, with multiple national and provincial science awards and 28 valid patents (including 18 invention patents) supporting its competitive position within China's veterinary biologics industry.

Name

扬州优邦生物药品有限公司

Legal name

金宇优邦生物科技（江苏）有限公司

Website

https://uni-bio.com.cn

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Yangzhou Uni-Bio is a Chinese veterinary vaccine manufacturer and wholly-owned subsidiary of Jinyu Bio (SHA: 600201), producing GMP-certified swine, poultry, waterfowl, and ruminant vaccines for commercial farms across China using proprietary baculovirus expression, cell suspension culture, and live viral vector platforms.

Ownership category

akta.pro rank

Product category

Veterinary Vaccines

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Poultry Vaccines (HLAMAKAC), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)

Keywords

• Veterinary vaccines
• Animal biological products
• Swine vaccines
• Poultry vaccines
• Livestock disease prevention

Headquarters

HQ city

Yangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Veterinary Biological Products Sales: Manufacturing and selling of veterinary vaccines for swine, poultry, and ruminants. Products include swine vaccines (porcine reproductive and respiratory syndrome, swine flu, pseudorabies, PCV2), poultry vaccines (Newcastle disease, avian influenza, infectious bronchitis, EDS), and waterfowl vaccines (gosling plague, duck Tembusu virus). Revenue from product sales through direct sales force.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Yangzhou Uni-Bio is a high-tech enterprise that researches, develops, manufactures, and sells veterinary biological products, primarily inactivated and live vaccines for pigs, poultry, waterfowl, and ruminants. The company operates 2 GMP workshops with 8 production lines covering 22 valid production approvals across swine vaccines (PRRS, swine flu, pseudorabies, PCV2), poultry vaccines (Newcastle disease, avian influenza, infectious bronchitis, infectious coryza), and waterfowl vaccines (gosling plague, duck Tembusu virus). Production is backed by proprietary platforms spanning baculovirus expression, live viral vector development, and large-scale cell suspension culture.

Product overview

扬州优邦生物药品有限公司是一家专业从事动物疫病预防、治疗用生物制品的研发、生产和销售的高新技术企业。公司属于金宇生物技术股份有限公司（股票代码600201）的全资子公司，主要生产猪用疫苗、禽用疫苗和水禽疫苗三大系列产品。公司拥有8条GMP生产线，生产猪苗、禽苗、牛苗等多个产品系列，包括猪繁殖与呼吸综合征灭活疫苗、猪圆环病毒2型杆状病毒载体灭活疫苗、鸡新城疫禽流感二联/三联/四联灭活疫苗、小鹅瘟灭活疫苗、鸭坦布苏病毒病活疫苗等22个有效生产文号产品。

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Endotoxin levels controlled at ≤5EU/dose, 10x stricter than national standard of 50EU
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• 南京农业大学 (Nanjing Agricultural University)coreStrategic or Co-development PartnerLong-standing university partnership. Joint research programs, student recruitment, and talent development. University faculty and students regularly visit the company for research and training. The company sponsors the 'Uni-Bio Cup' graduate academic three-minute speech competition at Yangzhou University.
• 扬州大学 (Yangzhou University)coreStrategic or Co-development PartnerThe company sponsors and cooperates with Yangzhou University's veterinary college. Hosts the 'Uni-Bio Cup' Third Graduate Academic Three-Minute Speech Competition annually with the veterinary college.
• 江苏省动物疫病防治工程技术研究中心 (Jiangsu Provincial Animal Disease Prevention and Control Engineering Technology Research Center)minorStrategic or Co-development PartnerProvincial-level innovation platform established at the company. One of the company's 6 provincial-level and above innovation platforms.
• 扬州市水禽疾病防治工程技术研究中心 (Yangzhou Waterfowl Disease Prevention Engineering Technology Research Center)minorStrategic or Co-development PartnerCity-level innovation platform focused on waterfowl disease prevention and control, located at the company.
• 江苏省企业技术中心 (Jiangsu Provincial Enterprise Technology Center)minorStrategic or Co-development PartnerProvincial-level enterprise technology center recognition and platform established at the company.
• 江苏省企业研究生工作站 (Jiangsu Provincial Enterprise Graduate Workstation)minorStrategic or Co-development PartnerPlatform for graduate student research and training at the company, co-established with universities.

Scale indicators12 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• 天津瑞普生物技术股份有限公司 (Ringpu Bio): Listed Chinese veterinary drug and vaccine company (Shenzhen: 300119) covering veterinary biologics, pharmaceuticals, and feed additives for livestock and poultry. Overlapping product portfolio with Uni-Bio in poultry and swine vaccines.
• 武汉科前生物股份有限公司 (Wuhan Keqian Biology): Listed Chinese veterinary vaccine maker (STAR Market: 688526) with strong R&D platform focus on pigs and poultry vaccines. Comparable technology positioning and similar reliance on R&D-driven product differentiation as Uni-Bio.
• 普莱柯生物工程股份有限公司 (Pulike Biological Engineering): Listed Chinese veterinary vaccine manufacturer (Shanghai: 603566) focused on genetically engineered vaccines for pigs and poultry. Directly comparable in product portfolio, R&D platform approach, and target customer segments to Yangzhou Uni-Bio.
• 永顺生物技术股份有限公司 (Shenzhen Rinbio): Chinese veterinary vaccine company listed on NEEQ with focus on classical and genetically engineered vaccines for pigs and poultry. Comparable in scale, regional focus, and product mix to Uni-Bio.
• 中牧实业股份有限公司 (China Animal Husbandry Industry / Zhongmu): State-owned veterinary vaccine and animal health company (Shanghai: 600195), one of China's largest. Competes with Uni-Bio across swine, poultry, and ruminant vaccine categories with broader product breadth and distribution scale.
• 金河生物科技股份有限公司 (Jinhe Bio): Listed Chinese veterinary pharmaceutical and vaccine company (Shenzhen: 002688) with products spanning veterinary APIs, premixes, and animal vaccines. Comparable in business model and target customer segments to Uni-Bio.
• 辽宁益康生物股份有限公司 (Liaoning Yikang Biological): Sister veterinary vaccine company within the Jinyu Bio group (explicitly linked on Uni-Bio's website), producing animal vaccines with overlap in poultry and livestock categories. Strongest internal comparable within the same parent corporate family.

Broad incumbents

• Elanco Animal Health: Global animal health company (NYSE: ELAN) with broad veterinary vaccine portfolio across livestock and companion animals. International incumbent competing in many of the same vaccine categories Uni-Bio targets, though at vastly larger scale.
• Zoetis: Global leader in animal health and veterinary vaccines (NYSE: ZTS). Operates broadly across species and geographies with overlapping vaccine portfolios for livestock and poultry, but at vastly larger scale and international footprint vs. Uni-Bio.
• Boehringer Ingelheim Animal Health: Global animal health division of Boehringer Ingelheim, one of the world's largest veterinary vaccine producers. Strong in swine and poultry vaccines globally with technology platform leadership relevant to Uni-Bio's positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E6%89%AC%E5%B7%9E%E4%BC%98%E9%82%A6%E7%94%9F%E7%89%A9%E8%8D%AF%E5%93%81%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 扬州优邦生物药品有限公司